FDA OKs COVID-19 Drug Veklury (remdesivir) for Outpatients, Opening the Way for 340B Pricing

Hospitals filled with patients infected with the highly infectious omicron variant of COVID-19 say they are very relieved to be getting 340B pricing finally on Gilead’s injectable antiviral medication Veklury (remdesivir).

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

FDA OKs COVID-19 Drug Veklury (remdesivir) for Outpatients, Opening the Way for 340B Pricing

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Tom Mirga